Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.

ABSTRACT: Estimates of the spectrum and frequency of pathogenic variants in Parkinson's disease (PD) in different populations are currently limited and biased. Furthermore, although therapeutic modification of several genetic targets has reached the clinical trial stage, a major obstacle in conducting these trials is that PD patients are largely unaware of their genetic status and, therefore, cannot be recruited. Expanding the number of investigated PD-related genes and including genes related to disorders with overlapping clinical features in large, well-phenotyped PD patient groups is a prerequisite for capturing the full variant spectrum underlying PD and for stratifying and prioritizing patients for gene-targeted clinical trials. The Rostock Parkinson's disease (ROPAD) study is an observational

SUBMITTER: Westenberger A 

PROVIDER: S-EPMC11292909 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature